1. Home
  2. SGA vs COCH Comparison

SGA vs COCH Comparison

Compare SGA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$5.92

Market Cap

56.6M

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$6.70

Market Cap

51.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGA
COCH
Founded
1986
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Blank Checks
Sector
Consumer Discretionary
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
51.3M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
SGA
COCH
Price
$5.92
$6.70
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $19.67
AVG Volume (30 Days)
16.1K
★ 33.3K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
★ 15.15%
N/A
EPS Growth
N/A
★ 17.45
EPS
★ N/A
N/A
Revenue
★ $124,829,000.00
$241,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$15.33
P/E Ratio
★ N/A
N/A
Revenue Growth
5.65
★ 7.11
52 Week Low
$6.55
$4.72
52 Week High
$12.76
$47.70

Technical Indicators

Market Signals
Indicator
SGA
COCH
Relative Strength Index (RSI) 19.91 19.07
Support Level N/A $4.72
Resistance Level $9.41 $7.46
Average True Range (ATR) 0.44 0.41
MACD -0.11 0.93
Stochastic Oscillator 25.87 20.83

Price Performance

Historical Comparison
SGA
COCH

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: